10 July 2017 | News
With this new development, GNH India has forayed into the UK market as a legal distributor of rare and life-saving drugs
A global source for priority pharmaceuticals, GNH India is amongst the handful of Indian companies to clear an audit from one of the largest UK pharmaceutical distribution companies.
Armed with a WHO-GDP (Good Distribution Practice) certification, GNH India has entered a two-way partnership with the UK based company for the trade in life-saving drugs into their respective countries.
The WHO-GDP certification ensures that procurement, purchasing, storage, distribution, transportation, repackaging, relabelling, documentation and record-keeping practices are met with stringent protocols
Through this new development, accessibility to medicines for the treatment of an array of diseases is now not just plausible; but extremely possible.
Orphan drugs such as Ferripox (used in the treatment of iron overload in Thalassaemia major patients), Raxone (used in the treatment of visually impaired adolescents and adults), Trientine (used to treat a rare but growing rate of Wilson’s disease) and Mitocin (a drug used to treat a range of cancers) are now available to the Indian population.
Commenting on this, Dr. Piyush Gupta, Associate Director, GNH India said, “With a change in lifestyle and increased travel abroad, India’s population has become a crucible for various diseases. Even though we have seen a marked increase in incidences of rare diseases, our pharmaceutical industry is yet to catch up in response to this growth trajectory. At GNH India, we had ensured to follow due protocol by applying and receiving the WHO-GDP certification well before hand. This has led to a high success rate in terms of clearing audits from various countries- the UK is the latest.”
"When these protocols are not met, the market is flooded with pseudo or counterfeit drugs. The efficacy of such medicines is a threat to public health and safety”, he added